However, either ABT‐737 or ABT‐263 lacks the binding affinity to Mcl‐1, which makes the Mcl‐1 up‐regulated cancer cells resistant to ABT‐737 and ABT‐263, thus limiting their clinical applications as a single agent 8, 9. The gene discussed is MCL1; the disease is cancer.